Clinical Trials

Breast Neoplasms

NCT02732119 2021-05-05

TRINITI-1

Phase 1/2 Completed

104 enrolled 24 charts

Breast Neoplasms

NCT01857193 2021-04-13

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

132 enrolled

Breast Neoplasms

NCT01783444 2021-02-26

BOLERO-6

309 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02392611 2020-12-29

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

33 enrolled 23 charts

Lymphoid

Lymphoma

NCT02077933 2020-12-08

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

79 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT03176238 2020-04-07

EVEREXES

235 enrolled 11 charts

Breast Neoplasms

NCT01743560 2019-07-18

4EVERUK

Phase 4 Completed

52 enrolled 16 charts

Breast Diseases, Breast Neoplasms, Neoplasms, Skin Diseases

NCT01597193 2019-05-08

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

101 enrolled 33 charts

Breast Neoplasms

NCT02833155 2019-05-07

Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer

19 enrolled

Breast Neoplasms

NCT01381874 2019-04-11

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

297 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01605396 2019-03-25

MK-8669-064

80 enrolled 13 charts

Breast Neoplasms

NCT01938846 2019-01-04

BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors

90 enrolled 22 charts

Tumor-Agnostic

Neoplasms

NCT00728949 2018-06-06

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

93 enrolled 14 charts

Breast Neoplasms

NCT01331421 2018-01-23

Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

Phase NA Completed

48 enrolled

Breast Neoplasms

NCT01331434 2018-01-23

Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions

Phase NA Completed

47 enrolled

Breast Neoplasms

NCT01331447 2018-01-23

Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

Phase NA Completed

12 enrolled

Breast Neoplasms

NCT02248571 2017-11-13

IMPROVE

Phase 4 Completed

85 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT01234857 2017-05-31

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

115 enrolled

Breast Neoplasms

NCT00863655 2017-05-02

BOLERO-2

724 enrolled 20 charts

Breast Neoplasms

NCT01626222 2017-02-23

MACS2096

301 enrolled

Breast Neoplasms

NCT02069093 2017-02-13

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

92 enrolled 9 charts

Advanced Breast Cancer

NCT01151046 2016-05-12

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

118 enrolled 13 charts

Breast Neoplasms

NCT01202591 2016-02-11

GLOW

Phase 1/2 Completed

127 enrolled 8 charts

Breast Neoplasms

NCT02023359 2015-12-29

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Completed

7 enrolled

Breast Neoplasms

NCT00036270 2015-10-28

TEAM

9,779 enrolled 13 charts

Breast Neoplasms

NCT01047358 2015-10-08

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

Completed

206 enrolled 9 charts

Breast Neoplasms

NCT01004081 2015-10-02

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

54 enrolled

Breast Neoplasms

NCT00065325 2015-02-24

EFECT

694 enrolled

Breast Neoplasms

NCT00038467 2014-05-07

IES

4,740 enrolled 31 charts